[Form 4] Arcellx, Inc. Insider Trading Activity
Arcellx insider sale under 10b5-1 plan. The chief medical officer sold 12,396 shares of Arcellx common stock under a Rule 10b5-1 trading plan, at a weighted average price of $80.119 per share, and now beneficially owns 21,731 shares. The filing reports the transaction as a sale and identifies the sale price range as $80.00 to $80.41 with the weighted average disclosed. The reporting person indicates the sale was pre-arranged under a March 23, 2025 10b5-1 plan and offers to provide breakdown by price on request.
Vendita da insider di Arcellx sotto piano 10b5-1. Il direttore medico ha venduto 12.396 azioni ordinarie di Arcellx nell'ambito di un piano di negoziazione Rule 10b5-1, a un prezzo medio ponderato di $80,119 per azione, e ora detiene beneficiariamente 21.731 azioni. La documentazione riporta la transazione come vendita e indica l'intervallo di prezzo di vendita da $80,00 a $80,41 con la media ponderata divulgata. Il soggetto che riporta la transazione indica che la vendita è stata pianificata in anticipo secondo un piano 10b5-1 datato 23 marzo 2025 e si offre di fornire una scomposizione per prezzo su richiesta.
Venta interna de Arcellx bajo plan 10b5-1. El director médico vendió 12.396 acciones ordinarias de Arcellx bajo un plan de negociación Rule 10b5-1, a un precio medio ponderado de $80,119 por acción, y ahora posee de manera beneficiosa 21.731 acciones. El archivo/reportación indica la transacción como una venta e identifica el rango de precio de venta entre $80,00 y $80,41 con el promedio ponderado divulgado. La persona reportante indica que la venta fue pre-arreglada bajo un plan 10b5-1 fechado el 23 de marzo de 2025 y ofrece proporcionar un desglose por precio a solicitud.
Arcellx 내부자 매각, 10b5-1 계획 하에. 최고 의료 책임자는 Rule 10b5-1 거래 계획에 따라 Arcellx 보통주 12,396주를 매도했으며 가중 평균가가 주당 $80.119로, 현재 혜택상 보유 주식은 21,731주이다. 신청서는 거래를 매도으로 보고하며 매도가격 범위를 $80.00 ~ $80.41로 명시하고 가중 평균을 공시한다. 보고자에 따르면 매매는 2025년 3월 23일자 10b5-1 계획에 따라 미리 예정되었으며 요청 시 가격별 세부 내역을 제공하겠다.
Vente d'initié Arcellx sous plan 10b5-1. Le directeur médical a vendu 12 396 actions ordinaires d'Arcellx dans le cadre d'un plan de négociation Rule 10b5-1, à un prix moyen pondéré de 80,119 $ par action, et détient désormais 21 731 actions de manière bénéficiaire. Le dépôt rapporte la transaction comme une vente et indique que la plage de prix de vente est de $80,00 à $80,41 avec la moyenne pondérée divulguée. La personne habilitée à déclarer indique que la vente a été préprogrammée dans le cadre d'un plan 10b5-1 daté du 23 mars 2025 et se propose de fournir une ventilation par prix sur demande.
Arcellx-Investorengang unter 10b5-1-Plan. Der Chief Medical Officer hat 12.396 Arcellx-Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans verkauft, zu einem gewichteten Durchschnittspreis von 80,119 USD pro Aktie, und besitzt nun vorteilhaft 21.731 Aktien. Die Einreichung meldet die Transaktion als Verkauf und gibt die Preisspanne von 80,00 USD bis 80,41 USD mit dem gewählten gewichteten Durchschnitt bekannt. Die meldende Person gibt an, dass der Verkauf unter einem am 23. März 2025 geschlossenen 10b5-1-Plan vorab vereinbart wurde und bietet auf Anfrage eine Preisaufteilung an.
بيع داخلي لشركة Arcellx بموجب خطة 10b5-1. باع رئيس الإدارة الطبية 12,396 سهمًا من أسهم Arcellx العادية في إطار خطة تداول Rule 10b5-1، بسعر متوسط مرجح قدره 80.119 دولارًا للسهم، وهو يملك الآن بشكل مستفيد 21,731 سهمًا. يُذكر في الملف أن المعاملة باعتبارها بيعًا، ويحدّد نطاق سعر البيع من 80.00 دولار إلى 80.41 دولار مع الكشف عن المتوسط المرجح. يشير الشخص المُبلغ إلى أن البيع تم ترتيبه مسبقًا بموجب خطة 10b5-1 المؤرخة في 23 مارس 2025، ويعرض تقديم تفصيل حسب السعر عند الطلب.
Arcellx 内部人根据 10b5-1 计划进行的出售。 首席医疗官在一项 10b5-1 交易计划下出售了 Arcellx 普通股 12,396 股，摊销后平均价格为每股 80.119 美元，现自有受益持有 21,731 股。文件将交易列为出售，并将出售价格区间标注为 80.00 美元至 80.41 美元，披露的加权平均价。报道人表示该出售是在 2025 年 3 月 23 日的 10b5-1 计划下预先安排的，如有需要可按价格提供分解。
- Sale executed under a Rule 10b5-1 trading plan, indicating a pre-established, non-discretionary disposition framework
- Weighted average sale price disclosed ($80.119) and a price range ($80.00 to $80.41), providing pricing transparency
- Reporting person offers to provide detailed price-by-price breakdown on request, supporting transparency
- Beneficial ownership decreased by the reported sale, leaving the reporting person with 21,731 shares
- No information provided on dollar value retained or percentage ownership relative to outstanding shares, limiting context for investors
Insights
TL;DR: Insider sold a portion of holdings via a 10b5-1 plan; remaining ownership is disclosed at 21,731 shares.
The transaction is an organized sale under a Rule 10b5-1 trading plan, which generally indicates pre-planned dispositions rather than opportunistic sales based on inside information. The sale size—12,396 shares at a weighted average of $80.119—reduced the reporting person's beneficial ownership to 21,731 shares. From a disclosure perspective, the filing is clean: it specifies the 10b5-1 plan date and provides the weighted average price and price range. No derivative transactions or other changes in ownership form are reported.
TL;DR: Governance disclosure follows standard practice; sale executed under an established trading plan with pricing transparency.
The Form 4 clearly states the sale was effected pursuant to a 10b5-1 trading plan entered on March 23, 2025, and discloses the aggregate shares sold and weighted average price. This provides reasonable governance transparency about the insider's liquidity event. The filer also commits to supplying itemized share-price sale details on request, which supports regulatory compliance and stakeholder transparency. No related-party transfers or indirect ownership changes are disclosed.
Vendita da insider di Arcellx sotto piano 10b5-1. Il direttore medico ha venduto 12.396 azioni ordinarie di Arcellx nell'ambito di un piano di negoziazione Rule 10b5-1, a un prezzo medio ponderato di $80,119 per azione, e ora detiene beneficiariamente 21.731 azioni. La documentazione riporta la transazione come vendita e indica l'intervallo di prezzo di vendita da $80,00 a $80,41 con la media ponderata divulgata. Il soggetto che riporta la transazione indica che la vendita è stata pianificata in anticipo secondo un piano 10b5-1 datato 23 marzo 2025 e si offre di fornire una scomposizione per prezzo su richiesta.
Venta interna de Arcellx bajo plan 10b5-1. El director médico vendió 12.396 acciones ordinarias de Arcellx bajo un plan de negociación Rule 10b5-1, a un precio medio ponderado de $80,119 por acción, y ahora posee de manera beneficiosa 21.731 acciones. El archivo/reportación indica la transacción como una venta e identifica el rango de precio de venta entre $80,00 y $80,41 con el promedio ponderado divulgado. La persona reportante indica que la venta fue pre-arreglada bajo un plan 10b5-1 fechado el 23 de marzo de 2025 y ofrece proporcionar un desglose por precio a solicitud.
Arcellx 내부자 매각, 10b5-1 계획 하에. 최고 의료 책임자는 Rule 10b5-1 거래 계획에 따라 Arcellx 보통주 12,396주를 매도했으며 가중 평균가가 주당 $80.119로, 현재 혜택상 보유 주식은 21,731주이다. 신청서는 거래를 매도으로 보고하며 매도가격 범위를 $80.00 ~ $80.41로 명시하고 가중 평균을 공시한다. 보고자에 따르면 매매는 2025년 3월 23일자 10b5-1 계획에 따라 미리 예정되었으며 요청 시 가격별 세부 내역을 제공하겠다.
Vente d'initié Arcellx sous plan 10b5-1. Le directeur médical a vendu 12 396 actions ordinaires d'Arcellx dans le cadre d'un plan de négociation Rule 10b5-1, à un prix moyen pondéré de 80,119 $ par action, et détient désormais 21 731 actions de manière bénéficiaire. Le dépôt rapporte la transaction comme une vente et indique que la plage de prix de vente est de $80,00 à $80,41 avec la moyenne pondérée divulguée. La personne habilitée à déclarer indique que la vente a été préprogrammée dans le cadre d'un plan 10b5-1 daté du 23 mars 2025 et se propose de fournir une ventilation par prix sur demande.
Arcellx-Investorengang unter 10b5-1-Plan. Der Chief Medical Officer hat 12.396 Arcellx-Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans verkauft, zu einem gewichteten Durchschnittspreis von 80,119 USD pro Aktie, und besitzt nun vorteilhaft 21.731 Aktien. Die Einreichung meldet die Transaktion als Verkauf und gibt die Preisspanne von 80,00 USD bis 80,41 USD mit dem gewählten gewichteten Durchschnitt bekannt. Die meldende Person gibt an, dass der Verkauf unter einem am 23. März 2025 geschlossenen 10b5-1-Plan vorab vereinbart wurde und bietet auf Anfrage eine Preisaufteilung an.
FAQ
What did Arcellx insider sell in the Form 4 (ACLX)?
At what price were the ACLX shares sold?
How many ACLX shares does the reporting person own after the sale?
Was this sale part of a pre-arranged plan?
Does the Form 4 report any option exercises or derivative transactions?
